Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Other Non-Current Assets: 2020-2025

Historic Other Non-Current Assets for Tango Therapeutics (TNGX) over the last 5 years, with Sep 2025 value amounting to $2.1 million.

  • Tango Therapeutics' Other Non-Current Assets fell 16.67% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 16.67%. This contributed to the annual value of $2.6 million for FY2024, which is 24.50% down from last year.
  • According to the latest figures from Q3 2025, Tango Therapeutics' Other Non-Current Assets is $2.1 million, which was down 0.00% from $2.1 million recorded in Q2 2025.
  • In the past 5 years, Tango Therapeutics' Other Non-Current Assets registered a high of $4.0 million during Q1 2022, and its lowest value of $2.1 million during Q1 2025.
  • For the 3-year period, Tango Therapeutics' Other Non-Current Assets averaged around $2.6 million, with its median value being $2.6 million (2024).
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first soared by 73.91% in 2022, then crashed by 35.82% in 2023.
  • Tango Therapeutics' Other Non-Current Assets (Quarterly) stood at $2.3 million in 2021, then soared by 73.91% to $4.0 million in 2022, then fell by 15.00% to $3.4 million in 2023, then dropped by 24.50% to $2.6 million in 2024, then decreased by 16.67% to $2.1 million in 2025.
  • Its last three reported values are $2.1 million in Q3 2025, $2.1 million for Q2 2025, and $2.1 million during Q1 2025.